Please assess the completion status of the following clinical trial:

Trial Title: pCHIP: Prostate Cancer Health Impact Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Established Prostate Cancer Group:~Inclusion Criteria:~* Participant must be designated male at birth~* Self-identified AA or H/L~* Be 18 years of age or older~* Fluent in English or Spanish~* Able to provide informed consent.~Exclusion Criteria:~* Patients or shared decision makers with cognitive or sensory impairment which impede their ability to provide informed consent as determined by consenting individual or documented in the medical record.~At Risk of Prostate Cancer Group:~Inclusion Criteria:~* Participant must be designated male at birth~* Self-identified AA or H/L~* Be 18 years of age or older~* Have stage I-III PCa, not yet begun cancer treatment~* Have no evidence of progressive disease or second primary cancer~Exclusion Criteria:~* Men who have already begun cancer treatment~* Have evidence of progressive disease~* Second primary cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Established Prostate Cancer Group (Type: None): Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
- At Risk of Prostate Cancer Group (Type: None): At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study).

Based on this trial design, predict the completion outcome and termination type (if applicable).